Motor Neuron Disease: Clinical Trials

1,355 trials for Motor Neuron Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

609 completed, 239 recruiting, 180 unknown, 91 terminated. 341 Phase 2, 336 Not applicable, 220 Phase 1, 123 Phase 3, 24 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2341Completed 184, Recruiting 37, Terminated 35, Unknown 33, Active not recruiting 21, Not yet recruiting 14, Withdrawn 11, Enrolling by invitation 4, Suspended 2
Not applicable336Completed 139, Recruiting 80, Unknown 52, Active not recruiting 17, Not yet recruiting 13, Withdrawn 13, Terminated 12, Enrolling by invitation 8, Suspended 2
Phase 1220Completed 101, Recruiting 31, Unknown 23, Terminated 22, Active not recruiting 15, Not yet recruiting 14, Withdrawn 7, Enrolling by invitation 4, Suspended 3
Phase 3123Completed 64, Terminated 18, Recruiting 13, Active not recruiting 12, Unknown 9, Not yet recruiting 6, Withdrawn 1
Early Phase 124Completed 9, Not yet recruiting 6, Recruiting 4, Active not recruiting 2, Withdrawn 2, Enrolling by invitation 1
Phase 418Completed 9, Unknown 4, Recruiting 3, Active not recruiting 2

Follow Motor Neuron Disease: new trials by email Literature Review of Motor Neuron Disease trials Research Report on Motor Neuron Disease

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN
Tetramethylpyrazine nitrone (TBN) tablet / Placebo - Healthy
Phase 1Not yet recruitingGuangzhou Magpie Pharmaceuticals Co., Ltd.162028-09-012026-09-11
Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)
B cell infusion - ALS - Amyotrophic Lateral Sclerosis
Phase 1Not yet recruitingMark Poznansky102027-09-012026-09-24
Safety Study of XT-150 in Participants With ALS
XT-150 - Amyotrophic Lateral Sclerosis (ALS)
Phase 1Not yet recruitingXalud Therapeutics, Inc.82027-03-012026-07-29
A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NI112, Placebo - Amyotrophic Lateral Sclerosis (ALS)
Phase 1Not yet recruitingSachi Bioworks Inc.402027-01-222026-10-30
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
INTENT Neural Interface System - Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS)
Not applicableRecruitingJohns Hopkins University52027-01-012026-10-09
SPX-01 Gene Therapy in Pediatric Patients With Spinal Muscular Atrophy Type 1 (RISE)
SPX-01 - Spinal Muscular Atrophy (SMA)
Early Phase 1Not yet recruitingExir Gene Pharmed12027-01-012026-10-29
Dorsal Root Ganglion Stimulation After Lower Motor Neuron Damage
Abbot Dorsal Root Ganglion Neurostimulator - Spinal Cord Injuries, Lower Motor Neuron Disease
Not applicableNot yet recruitingPeter J. Grahn, Ph.D.12026-12-012026-09-15
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
Q-Cells - Amyotrophic Lateral Sclerosis
Phase 1 / Phase 2Not yet recruitingQ Therapeutics, Inc.302026-12-012026-07-08
Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS
nL-TARDB-002 - Amyotrophic Lateral Sclerosis (ALS)
Phase 1 / Phase 2Enrolling by invitationn-Lorem Foundation12026-12-012026-07-14
Brain-Computer Interface Communication Device for People With ALS
Cognixion ONE AR-BCI configuration, Cognixion ONE screen-based BCI configuration, Existing eye-gaze speech generating device - Amyotrophic Lateral Sclerosis
Not applicableRecruitingCognixion302026-11-152026-10-16
A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi Arabia
Spinal Muscular Atrophy
Not yet recruitingNovartis Pharmaceuticals62026-11-012026-10-15
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
LY3873862, CYP450 Drug Cocktail, Placebo - Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Phase 1Not yet recruitingEli Lilly and Company322026-11-012026-10-20
A Registry of Cases of Spinal Muscular Atrophy
Spinal Muscular Atrophy
RecruitingSt. Jude Children's Research Hospital302026-11-012026-10-22
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
IBM, Inclusion Body Myositis
RecruitingJohns Hopkins University302026-11-012026-10-28
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
Salanersen, Sham Procedure - Muscular Atrophy, Spinal
Phase 3RecruitingBiogen422026-10-312026-10-15
Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
Portable Isokinetic Knee Training Robot With an Individually Optimized Compliant Setting, Portable Isokinetic Knee Training Robot With a Rigid Setting - Spinal Muscular Atrophy (SMA)
Not applicableRecruitingPeking University Third Hospital132026-10-222026-10-23
Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)
Chronic speech BCI - Locked in Syndrome, ALS (Amyotrophic Lateral Sclerosis)
Not applicableNot yet recruitingUniversity Hospital, Grenoble32026-10-102026-07-13
A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)
BIIB147, Placebo - Amyotrophic Lateral Sclerosis
Phase 1 / Phase 2RecruitingBiogen692026-10-072026-10-26
A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients
Spinal Muscular Atrophy
RecruitingNovartis Pharmaceuticals802026-10-072026-10-22
iBCI Optimization for Veterans With Paralysis
Mobile neural decoding platform (mobile iBCI) - Spinal Cord Injury, Amyotrophic Lateral Sclerosis
Not applicableNot yet recruitingVA Office of Research and Development22026-10-022026-07-27

Showing 20 of 1355. Sign in to see all of them.

Narrower conditions

Amyotrophic Lateral Sclerosis (974)  ·  Muscular Atrophy, Spinal (280)  ·  Neuromuscular Diseases (72)  ·  Spinal Muscular Atrophies of Childhood (61)  ·  Bulbo-Spinal Atrophy, X-Linked (57)  ·  Parkinson Disease (53)  ·  Neurodegenerative Diseases (50)  ·  Spinal Cord Injuries (45)  ·  Alzheimer Disease (35)  ·  Multiple Sclerosis (34)  ·  Frontotemporal Dementia (31)  ·  Nervous System Diseases (29)  ·  Muscular Dystrophies (28)  ·  Stroke (28)

Broader conditions

Nervous System Diseases (1326)  ·  Central Nervous System Diseases (1306)  ·  Neurodegenerative Diseases (1305)  ·  Spinal Cord Diseases (1302)  ·  Neuromuscular Diseases (1283)  ·  Nutritional and Metabolic Diseases (985)  ·  Metabolic Diseases (983)  ·  Proteostasis Deficiencies (974)  ·  TDP-43 Proteinopathies (969)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (199)  ·  Pathological Conditions, Signs and Symptoms (195)  ·  Genetic Diseases, Inborn (194)  ·  Heredodegenerative Disorders, Nervous System (153)  ·  Brain Diseases (134)

Interventions

nusinersen (28)  ·  Riluzole (24)  ·  Blood Specimen Collection (19)  ·  Risdiplam (18)  ·  Zolgensma (13)  ·  Spinal Puncture (10)  ·  Surveys and Questionnaires (9)  ·  Dexpramipexole (8)  ·  Edaravone (8)  ·  Exercise (8)  ·  Sodium Chloride (7)  ·  sodium phenylbutyrate and taurursodiol (7)  ·  4-phenylbutyric acid (6)  ·  CK-2017357 (6)  ·  Noninvasive Ventilation (6)

Sponsors

Biogen (36)  ·  Assistance Publique - Hôpitaux de Paris (28)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (26)  ·  Peking University Third Hospital (23)  ·  Massachusetts General Hospital (21)  ·  Novartis Pharmaceuticals (20)  ·  Hoffmann-La Roche (19)  ·  Columbia University (15)  ·  Johns Hopkins University (12)  ·  University of Michigan (11)  ·  Cytokinetics (10)  ·  Drexel University College of Medicine (10)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (10)  ·  Mayo Clinic (10)  ·  Duke University (9)

Countries

United States (592)  ·  France (179)  ·  Italy (142)  ·  United Kingdom (120)  ·  Germany (117)  ·  Canada (112)  ·  China (94)  ·  Belgium (87)  ·  Spain (87)  ·  Netherlands (85)  ·  Australia (60)  ·  Poland (51)  ·  Japan (44)  ·  Sweden (38)  ·  Ireland (35)

Top investigators

Merit Cudkowicz, MD (10)  ·  Jeremy Shefner, MD, PhD (8)  ·  Bjorn Oskarsson, MD (6)  ·  Dominic Rowe, MD (5)  ·  Dongsheng Fan (5)  ·  Mary Kay Floeter, M.D. (5)  ·  Merit Cudkowicz, MD, MSc (5)  ·  Terry Heiman-Patterson, MD (5)  ·  Benjamin R Brooks, MD (4)

Results publications

PMID 31420846, PMID 34383289, PMID 37148485, PMID 27939059, PMID 36008843, PMID 38705943, PMID 41224659, PMID 16434671, PMID 17980667, PMID 18506712, PMID 19251627, PMID 19440247, PMID 22415951, PMID 22529995, PMID 23300829, PMID 23463272, PMID 23952636, PMID 24067398, PMID 25982504, PMID 26247043, PMID 26751635, PMID 26823478, PMID 28284873, PMID 29091570, PMID 29287521, PMID 29443664, PMID 30048507, PMID 30124008, PMID 30814647, PMID 30879249, PMID 32896088, PMID 34433481, PMID 34536404, PMID 35532908, PMID 35577511, PMID 35790423, PMID 37254449, PMID 37396808, PMID 38010108, PMID 39287519, PMID 39457678, PMID 40067754, PMID 40067755, PMID 40067821, PMID 41366786, PMID 42016922, PMID 10540002, PMID 10826123, PMID 11015796, PMID 11050032

NIH funding

2023 (21), 2025 (11), 2017 (10), 2014 (6), 2015 (5), 2019 (5), 2016 (4), 2018 (3), U54NS092091 (3), 1OT2NS136938 (2), 1OT2NS136939 (2), N01NS42361 (2), P01AG066597 (2), P01NS084974 (2), R01DC021714 (2)